| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/12/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 06/08/2023 |
4
| Postma Robert W (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 06/08/2023 |
4
| Hofmeister Robert (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 06/08/2023 |
4
| Thistle Mary (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 06/08/2023 |
4
| Huang James (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 06/08/2023 |
4
| Vieser Jaime (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 06/08/2023 |
4
| Weis Holger (Director) has filed a Form 4 on Alaunos Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $0.48, valued at
$48k
|
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 04/03/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/07/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/07/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| MSD Partners, L.P. reports a 7% stake in Alaunos Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| DISCOVERY CAPITAL MANAGEMENT, LLC / CT reports a 6.7% stake in Alaunos Therapeutics, Inc. |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 3.8% stake in Alaunos Therapeutics Inc. |
| 01/20/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Quarterly results |
|